{"title":"多组学分析显示,经典汤通过调节色氨酸代谢、肠道菌群稳态和线粒体Bax/Bcl-2途径缓解溃疡性结肠炎","authors":"Xujin Yang , Shen Peng , Ping Wang , Yi Tao","doi":"10.1016/j.jpba.2025.116972","DOIUrl":null,"url":null,"abstract":"<div><div>Gegen Qinlian Decoction (GQD), a classic decoction documented in the Treatise on Febrile Diseases, is clinically used to treat ulcerative colitis (UC). However, the active components and underlying pharmacological mechanisms of GQD in UC remain inadequately explored. Herein, we identify the active components and elucidate the underlying pharmacological mechanisms of GQD in the treatment of UC. A mouse model of UC was induced using dextran sulfate sodium (DSS) and treated with low, medium, and high doses of GQD. The therapeutic effects were assessed by monitoring body weight, disease activity index (DAI), colon length, spleen index, pathological changes, and cytokine levels. Plasma biomarkers were analyzed using Ultra-Performance Liquid Chromatography Quadrupole-Orbitrap mass spectrometer (UPLC-Q-Orbitrap MS)-based metabolomics. Changes in gut microbiota were also examined to identify key microbes involved in the intestinal pathological shifts. Additionally, network pharmacology analysis was conducted to predict the potential pathways of GQD in UC, which were subsequently validated by western blotting and ELISA assays. GQD significantly improved UC symptoms.A total of 98 chemical constituents in GQD were identified. Of these, 25 differential metabolites were found between normal and UC mice, with GQD modulating 22 of these metabolites. Metabolic pathways related to tryptophan, arginine, and proline were normalized. Network pharmacology predicted the apoptosis pathway as a potential target for GQD in UC intervention. Further experiments confirmed that GQD reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and downregulated the Bax/Bcl-2 apoptosis pathway. Moreover, gut microbiota analysis showed that GQD enhanced the diversity and abundance of beneficial bacteria. GQD alleviates UC by modulating tryptophan, arginine, and proline metabolism, maintaining gut microbiota balance, and reducing apoptosis in intestinal cells.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"264 ","pages":"Article 116972"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multi-omics analysis reveals classic decoction alleviates ulcerative colitis by modulating tryptophan metabolism, gut microbiota homeostasis, and mitochondrial Bax/Bcl-2 pathways\",\"authors\":\"Xujin Yang , Shen Peng , Ping Wang , Yi Tao\",\"doi\":\"10.1016/j.jpba.2025.116972\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Gegen Qinlian Decoction (GQD), a classic decoction documented in the Treatise on Febrile Diseases, is clinically used to treat ulcerative colitis (UC). However, the active components and underlying pharmacological mechanisms of GQD in UC remain inadequately explored. Herein, we identify the active components and elucidate the underlying pharmacological mechanisms of GQD in the treatment of UC. A mouse model of UC was induced using dextran sulfate sodium (DSS) and treated with low, medium, and high doses of GQD. The therapeutic effects were assessed by monitoring body weight, disease activity index (DAI), colon length, spleen index, pathological changes, and cytokine levels. Plasma biomarkers were analyzed using Ultra-Performance Liquid Chromatography Quadrupole-Orbitrap mass spectrometer (UPLC-Q-Orbitrap MS)-based metabolomics. Changes in gut microbiota were also examined to identify key microbes involved in the intestinal pathological shifts. Additionally, network pharmacology analysis was conducted to predict the potential pathways of GQD in UC, which were subsequently validated by western blotting and ELISA assays. GQD significantly improved UC symptoms.A total of 98 chemical constituents in GQD were identified. Of these, 25 differential metabolites were found between normal and UC mice, with GQD modulating 22 of these metabolites. Metabolic pathways related to tryptophan, arginine, and proline were normalized. Network pharmacology predicted the apoptosis pathway as a potential target for GQD in UC intervention. Further experiments confirmed that GQD reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and downregulated the Bax/Bcl-2 apoptosis pathway. Moreover, gut microbiota analysis showed that GQD enhanced the diversity and abundance of beneficial bacteria. GQD alleviates UC by modulating tryptophan, arginine, and proline metabolism, maintaining gut microbiota balance, and reducing apoptosis in intestinal cells.</div></div>\",\"PeriodicalId\":16685,\"journal\":{\"name\":\"Journal of pharmaceutical and biomedical analysis\",\"volume\":\"264 \",\"pages\":\"Article 116972\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmaceutical and biomedical analysis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0731708525003139\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, ANALYTICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical and biomedical analysis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0731708525003139","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
Multi-omics analysis reveals classic decoction alleviates ulcerative colitis by modulating tryptophan metabolism, gut microbiota homeostasis, and mitochondrial Bax/Bcl-2 pathways
Gegen Qinlian Decoction (GQD), a classic decoction documented in the Treatise on Febrile Diseases, is clinically used to treat ulcerative colitis (UC). However, the active components and underlying pharmacological mechanisms of GQD in UC remain inadequately explored. Herein, we identify the active components and elucidate the underlying pharmacological mechanisms of GQD in the treatment of UC. A mouse model of UC was induced using dextran sulfate sodium (DSS) and treated with low, medium, and high doses of GQD. The therapeutic effects were assessed by monitoring body weight, disease activity index (DAI), colon length, spleen index, pathological changes, and cytokine levels. Plasma biomarkers were analyzed using Ultra-Performance Liquid Chromatography Quadrupole-Orbitrap mass spectrometer (UPLC-Q-Orbitrap MS)-based metabolomics. Changes in gut microbiota were also examined to identify key microbes involved in the intestinal pathological shifts. Additionally, network pharmacology analysis was conducted to predict the potential pathways of GQD in UC, which were subsequently validated by western blotting and ELISA assays. GQD significantly improved UC symptoms.A total of 98 chemical constituents in GQD were identified. Of these, 25 differential metabolites were found between normal and UC mice, with GQD modulating 22 of these metabolites. Metabolic pathways related to tryptophan, arginine, and proline were normalized. Network pharmacology predicted the apoptosis pathway as a potential target for GQD in UC intervention. Further experiments confirmed that GQD reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and downregulated the Bax/Bcl-2 apoptosis pathway. Moreover, gut microbiota analysis showed that GQD enhanced the diversity and abundance of beneficial bacteria. GQD alleviates UC by modulating tryptophan, arginine, and proline metabolism, maintaining gut microbiota balance, and reducing apoptosis in intestinal cells.
期刊介绍:
This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome.
Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.